Table Four –

Effect of digoxin on HF hospitalization, Death, Total hospitalizations and suspected digoxin toxicity by quartile of predicted risk of HF hospitalization in the DIG Main Study

		Placebo Risk	DigoxinRisk	RR**	95% CI	OR*	95% CI	ARD	95% CI
HF Hosp	Overall	0.35	0.27			0.69	0.62–0.76	0.08	0.06–0.10
	Q1	0.20	0.17			0.84	0.66–1.08	0.03	−0.01–0.06
	Q2	0.28	0.22			0.73	0.59–0.91	0.06	0.02–0.10
	Q3	0.39	0.29			0.63	0.52–0.78	0.10	0.06–0.15
	Q4	0.52	0.39			0.58	0.48–0.71	0.13	0.09–0.18
						*p-value interaction = 0.11
Death	Overall	0.35	0.35			0.99	0.89–1.09	0.00	−0.02 −0.03
	Q1	0.17	0.18			1.05	0.82–1.35	−0.01	−0.04−(0.03)
	Q2	0.28	0.27			0.95	0.77–1.18	0.01	−0.03–(0.05)
	Q3	0.39	0.39			0.98	0.81–1.19	0.00	−0.04–(0.05)
	Q4	0.56	0.55			0.97	0.80–1.17	0.01	−0.04–(0.06)
						*p-value interaction = 0.94
Total Hosp/person-year	Overall	0.68	0.64	0.94	0.91–0.96			0.04	0.02–0.07
	Q1	0.42	0.50	1.18	1.09–1.27			−0.08	−0.11–(−0.04)
	Q2	0.59	0.54	0.92	0.85–0.98			0.05	0.01–0.09
	Q3	0.77	0.65	0.85	0.80–0.94			0.11	0.07–0.16
	Q4	1.05	0.93	0.89	0.83–0.94			0.12	0.06–0.18
				** p-value interaction <0.001
Suspected Dig Toxicity	Overall	0.01	0.02			2.19	1.43–3.36	−0.01	−0.02–0.00
	Q1	0.00	0.01			5.91	1.32–26.51	−0.01	−0.02–0.00
	Q2	0.01	0.01			1.91	0.64–5.72	−0.01	−0.01–0.00
	Q3	0.01	0.02			1.64	0.77–3.50	−0.01	−0.02–0.00
	Q4	0.02	0.03			2.16	1.11–4.20	−0.02	−0.03–0.00
						*p-value interaction = 0.43

HF heart failure; RR Risk ratio; OR odds ratio; ARD absolute risk difference; Q1 quartile 1; Q2 quartile 2; Q3 quartile 3; Q4 quartile 4. Hosp hospitalization; Dig digoxin. ARD is calculated as placebo-digoxin study group for all analyses